Mar 26, 2015 - timing of data from ongoing clinical studies, whether interim results from a clinical trial will be predi
Corporate Presentation! March 2015! !
2013Statements! Accomplishments! Forward Looking This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forwardlooking statements. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘potential,’’ ‘‘will,’’ ‘‘would,’’ ‘‘could,’’ ‘‘should,’’ ‘‘continue,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors, including: uncertainties inherent in the initiation of future clinical studies, expectations of expanding ongoing clinical studies, availability and timing of data from ongoing clinical studies, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical studies will be indicative of the results of future studies, expectations for regulatory approvals, development progress of the Company’s companion diagnostics, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the financial performance of the Company, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2015. !
2!
26 MARCH 2015!
2013 Accomplishments ! Epizyme Investment Highlights! !
Pioneers and leaders in histone methyltransferase (HMT) inhibitors!
•
Two first-in-class HMT inhibitors in the clinic!
– –
•
Objective responses in three target patient populations including more sizable and targeted orphan populations:!
– – –
• • • • •
Novel targets: EZH2 and DOT1L! Patent expiries in 2032!
Follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), including one durable complete response (CR)! INI1-deficient tumor: Malignant Rhabdoid Tumor (MRT), with one durable CR! MLL-r acute leukemia, including two CRs (orphan drug status granted)!
Global rights (ex-Japan) on EZH2i and US rights on DOT1Li! Partnerships with Celgene, GlaxoSmithKline and Eisai ! Product platform generating pipeline of novel therapeutic programs! Strong intellectual property estate! Ended 2014 with $190.1 million in cash and cash equivalents!
–
In addition, raised gross proceeds of $124.5 million in a follow-on offering in March 2015!
! !!
3
26 MARCH 2015!
Seasoned Management Team with !Deep Industry 2013 Accomplishments Expertise!
Robert Gould, Ph.D.! President and CEO!
Andrew Singer! Chief Financial Officer!
!
4
• 20 years at Merck in positions of increasing leadership, including VP of Licensing and External Research! • Former Director of Novel Therapeutics at the Broad Institute of MIT and Harvard ! • B.A. from Spring Arbor College, Ph.D. from University of Iowa!
• Nearly 20 years of financial experience, with 15 years in life sciences field! • Former Managing Director, Healthcare Investment Banking in Life Sciences Group at RBC Capital Markets! • B.A. from Yale University, M.B.A. from Harvard Business School!
Robert Copeland, Ph.D.! President of Research! and CSO!
• Former Vice President, Cancer Biology at GSK! • Held scientific positions of increasing leadership at Merck and BMS! • Held faculty position at University of Chicago Pritzker School of Medicine! • B.S. from Seton Hall University, Ph.D. from Princeton University !
• Former Vice President of Oncology Development at J&J! • Former Senior Vice President of Oncology at GSK! • Former fellow at DanaFarber, NCI and FDA! • B.A. from Johns Hopkins, M.D. and Ph.D. from Yale University School of Peter Ho, M.D., Ph.D.! Chief Development Officer! Medicine!
26 MARCH 2015!
Increasing Interest in Epigenetic Targets in 2013 Accomplishments ! Oncology!
!
5
26 MARCH 2015!
Pioneers and 2013 Leaders in the Field of! Histone Accomplishments Methyltransferase (HMT) Inhibitors! • HMTs are part of a regulatory system that controls gene expression, called epigenetics!
• HMTs turn gene expression off and on by placing methyl marks on histones!
• Genetic alterations can impact HMT activity, making them oncogenic due to misregulated gene expression!
• 96-member target class! ! !
!
6
Clinically advancing proprietary HMT inhibitor candidates from an efficient research operation with deep scientific, clinical and managerial expertise! !
26 MARCH 2015!
Pipeline of First-In-Class Epigenetic! 2013 Accomplishments Therapeutics: EPZ-6438! Preclinical Development!
Phase 1!
Phase 2!
EPZ-6438 EZH2! Phase 1 Dose Escalation and Dose Expansion:! NHL and Advanced Solid Tumors!
Dose escalation: n=24 Fully enrolled! Dose expansion: n=12 Fully enrolled!
Phase 2 NHL: Germinal Center DLBCL, Wild-Type EZH2!
n=30 Initiation 2Q!
Phase 2 NHL: Germinal Center DLBCL, Mutant EZH2!
n=30 Initiation 2Q!
Phase 2 NHL: Follicular Lymphoma, Wild-Type EZH2!
n=30 Initiation 2Q!
Phase 2 NHL: Follicular Lymphoma, Mutant EZH2!
n=30 Initiation 2Q!
Phase 2 NHL: Non-Germinal Center DLBCL!
n=30 Initiation 2Q!
Phase 2: Adult INI1-Deficient Tumors! Phase 1: Pediatric INI1-Deficient Tumors! Phase 1: Food Effect! Phase 1: Drug-Drug Interaction!
2015 Initiation Planned!
!
7
26 MARCH 2015!
study under design! study under design! n=12 Initiated March 2015! n=12 Initiation 2Q!
Pipeline of First-In-Class Epigenetic! 2013 Accomplishments Therapeutics: Additional Targets! Preclinical Development!
Phase 1!
Phase 2!
EPZ-5676 DOT1L! Phase 1 Dose Escalation and Dose Expansion:! Adult Acute Leukemias!
Dose escalation: n=25 Fully enrolled! Dose expansion: under enrollment!
Phase 1 Dose Escalation and Dose Expansion:! Pediatric Acute Leukemias!
Dose escalation: under enrollment!
GSK Targets! PRMT5! Undisclosed Target! Undisclosed Target!
Novel HMT Targets! Solid Tumors! Hematologic Malignancies!
8!
26 MARCH 2015!
Clinical Validation HMT Targets, !Pipeline 2013 of Accomplishments Progress! Clinical Progress! ü Demonstrated durable objective responses in Phase 1 study of EPZ-6438 (EZH2i) in relapsed/ refractory NHL and advanced solid tumor patients, as of October 20, 2014:!
• Partial response (PR) or better in three of five DLBCL patients, including one durable CR! • Durable PR in one follicular lymphoma patient! • Durable CR in one of two INI1-deficient solid tumor patients! ü Demonstrated clinical and biological activity in Phase 1 study of EPZ-5676 (DOT1Li) in adult MLL-r patients! •
Two CRs and one PR achieved in Phase 1 dose escalation study!
ü Initiated expansion cohorts in both clinical programs! ü Initiated EPZ-5676 Phase 1 study in pediatric MLL-r patients!
Pipeline Milestones! ü Demonstrated in vivo and in vitro activity of first-in-class PRMT5 inhibitor in models of mantle cell lymphoma in pre-clinical study data presented at ASH – 1st target in GSK collaboration! ü $2 million lead candidate milestone for 2nd target in GSK collaboration; $4 million lead candidate milestone and license payment for 3rd target in GSK collaboration ! ü Two issued patents and one notice of issuance granted for PRMT5 inhibitors; one issued patent covering PRMT1 inhibitors; patent applications published on novel chemical matter against multiple HMT targets, including CARM1, PRMT1, PRMT3, PRMT6, PRMT8!
!
9
26 MARCH 2015!
EPZ-6438! 2013 Accomplishments! First-in-Class, Oral, Selective Inhibitor of EZH2! •
First EZH2 inhibitor to enter clinical trials and demonstrate durable objective responses in multiple patient populations!
•
Potent and selective for wild type and mutant EZH2; clinical activity demonstrated in both germinal center and non-germinal center NHL with wild-type EZH2!
•
Durable objective responses as a monotherapy in DLBCL, FL and INI1-deficient patients as of October 20, 2014:!
– Three of five DLBCL, including one durable complete response (14+ months)! – One of four FL! – One of two INI1-deficient, including one durable complete response (8+ months)! • Generally well tolerated! – No treatment-related discontinuations as of October 20 data cut-off! – Ongoing duration of treatment for patients still on study: 7 months to 14 months as of January 2015!
• Safety, tolerability and oral dosing suggest possibility for combinations with other NHL therapies ! • Continuing to explore a broad spectrum of cancer indications and treatment combinations preclinically!
• Exclusive worldwide rights outside of Japan! • Long patent runway: composition of matter patent protection through 2032!
!
10
26 MARCH 2015!
Multiple Genetic2013 & Pharmacological Factors May Accomplishments ! Sensitize B-Cell Lymphomas to EZH2 Inhibitors! EZH2! Hot Spot Muts!
Concurrent Treatment with Corticosteroids!
WildType &! Mutant! EZH2!
Concurrent Treatment with BCL2 & 6! Inhibitors!
Concurrent Treatment with! B-Cell! Signaling Inhibitors!
MLL! LoF Muts!
EZH2! ê! H3K27me3!
PRC2 Subunit Amp/! Overexpression! Wild-Type! EZH2!
11!
26 MARCH 2015!
HAT! LoF Muts!
KDM6A! LoF Muts!
WildType! EZH2!
2013 Accomplishments EPZ-6438 First-in-Human Phase 1 !Study! Study design: Open-label, multicenter! • Single agent, oral BID dosing,
28-day cycles! • Histologic/cytologically confirmed advanced solid tumors or B-cell lymphomas! • “3+3” dose escalation design!
400 mg! 200 mg! (n = 3)! 100 mg! (n = 3)! (n = 6)!
1600 mg! 800 mg! (n = 6)! (n = 6)!
Primary Endpoint! • MTD/RP2D! Secondary Endpoints! • Safety! • PK! • Anti-tumor activity! • • • •
Safety assessments: ! Baseline, D1 and D15 of every cycle! Tumor assessments: ! Baseline and every 8 weeks! PK samples: ! Cycle 1, D1 and D15; Cycle 2 D1! Skin biopsies: ! Baseline and Cycle 2 D1!
Study initiation: June 2013!
BID, twice daily; D, day; MTD, maximum tolerated dose; PK, pharmacokinetics; RP2D, recommended Phase 2 dose ! 12!
26 MARCH 2015!
12
Four of First 10 Evaluable B-Cell Lymphoma 2013 Accomplishments ! Patients Continue on Therapy as of January 2015! • • • •
Ten evaluable patients first reported on at EORTC-NCI-AACR in November 2014! Four of ten patients reported on in November 2014 continue on study beyond 7 months (range 7 to 14 months), as of January 23, 2015! Twelve additional patients enrolled in 800 mg and 1600 mg expansion cohorts, not reflected in table! Continued evolution of responses in these patients is not reflected in this table !
Type! DLBCL!
FL!
MZL!
Cell-of-origin!
Dose! (mg BID)!
Best Response as of 10/20/14!
GCB1!
100!
PR!
Non-GCB2!
200!
CR!
Non-GCB!
200!
PD!
Non-GCB!
800!
PR!
Non-GCB!
800!
PD!
GCB!
400!
SD!
GCB!
800!
SD!
GCB!
800!
PR!
GCB!
1600!
SD!
Non-GCB!
1600!
SD!
1Transformed 2Primary
13! 13
follicular lymphoma ! mediastinal B-cell lymphoma!
26 MARCH 2015!
CR, complete response; PR, partial response; ! SD, stable disease; PD, progressive disease!
Objective Responses Seen in Four !of 10 B-Cell 2013 Accomplishments Lymphoma Patients! Data presented in November 2014 at EORTC-NCI-AACR! Data cut-off: October 20, 2014! 150!
Lymphoma!
Percent change from baseline!
125!
!DLBCL (GCB)! !DLBCL (non-GCB)!
100!
!FL! 75!
!MZL!
50! 25! 0! −25! −50!
PR! PR!
−75!
CR!
PR!
−100! 0! CR, complete response; PR, partial response; ! SD, stable disease; PD, progressive disease ! 14! 14
8!
16!
24!
Time (week)! 26 MARCH 2015!
32!
40!
Durable Complete Response in Primary 2013 Accomplishments ! Mediastinal B-Cell Lymphoma (Non-GCB) Patient! • • • •
Male, 23 years! ECOG 0! EZH2WT! Clinical history:! • Diagnosed Feb 2013! • Refractory to salvage therapy:! • R-ACVBP + methotrexate! • R-DHAP! • R-ICE! • Treatment: 200 mg PO BID! • Response:! • Complete response ongoing! • Still on study as of January 23, 2015 (14+ months on treatment)!
27/11/2013 Baseline 35 x 27 mm !
31/01/2014 Stable Disease 29 x 17 mm!
11/09/2014 FDG-PET: Complete Response! 15! 15
26 MARCH 2015!
Other Genetic2013 Factors May Sensitize Accomplishments ! Solid Tumors to EZH2 Inhibitors! Normal Cells: Balance between PRC2 (EZH2 complex) & SWI/SNF remodeling of chromatin ! SAM&
PRC2!
AEBP2&
EZ
SUZ12& RbAp48&
&&&& H2
SAH&
&
EED&
INI1!
SWI/SNF!
ADP!
ATP!
Tumor Cells: Changes within SWI/SNF create addiction to PRC2 (e.g. INI1 deficiency)! SAM&
AEBP2&
PRC2!
E
SUZ12& RbAp48&
&& 2&& ZH EED&
X!
INI1!
SWI/SNF! X! 16!
26 MARCH 2015!
&
ATP!
SAH&
Durable Complete Response Seen in INI1-Deficient 2013 Accomplishments ! MRT Patient among Solid Tumor Population! 9/05/2014!
• Male, 55 years! • ECOG 0! • INI1 loss (gene sequencing & IHC)! • Clinical history:! – MRT of cerebellum in 2013! – Definitive surgery and
adjuvant radiotherapy! – Recurrence in the cervical nodes!
21/05/2014! 15.2 mm! Baseline!
• Treatment: 800 mg PO BID! • Response:! – Complete response ongoing! – Still on study as of January 23, 2015 (8+ months on treatment)!
!
17! 17
26 MARCH 2015!
17/07/2014! 6.7 mm! Partial Response!
25/06/2014!
11/09/2014! 5.5 mm! Complete Response!
2013 Accomplishments ! Acceptable Safety Profile! Parameter! AEs!
! • Data cut-off: October 20, 2014! • 1 DLT occurred at
1600 mg BID! – Grade 4 thrombocytopenia with concurrent sepsis!
22 (92)! Treatment-related!
Grade ≥3 AEs! Treatment-related! Serious AEs! Treatment-related!
16 (67)! 5 (21)! 1 (4)! 4 (17)! 1 (4)!
AEs leading to! Drug withdrawal !
0!
Dose reduction!
0!
Dose interruption! Median no. of cycles received! AEs, adverse events; BID, twice daily; DLT, dose-limiting toxicity!
18! 18
Overall (N=24), n (%)!
26 MARCH 2015!
3 (13)! 3!
Two Phase 2 Studies and One Phase 2013 Accomplishments ! 1 Study Planned for 2015! Phase 2 Study of EPZ-6438 in Relapsed/ Refractory (R/R) B-Cell Non-Hodgkin Lymphoma! n=150; 800 mg BID! Expected initiation: 2Q15 in Europe! Incidence: 155,000 patients* ! Phase 2 Study of EPZ-6438 in Adult INI1-Deficient Tumors, including Synovial Sarcoma! Expected initiation: 2H15! Incidence: 1,700*
! Phase 1 Study of EPZ-6438 in Pediatric INI1-Deficient Tumors, including Malignant Rhabdoid Tumors! Expected initiation: 2H15! Incidence: 700*!
19!
*Incidence figures for major markets!
26 MARCH 2015!
R/R Germinal Center DLBCL! Wild-Type EZH2! n=30! Incidence: 24,000* ! R/R Germinal Center DLBCL! Mutant EZH2! n=30! Incidence: 6,000*! R/R Follicular Lymphoma! Wild-Type EZH2 ! n=30! Incidence: 30,000* ! R/R Follicular Lymphoma ! Mutant EZH2 ! n=30! Incidence: 6,000*! R/R Non-Germinal Center ! DLBCL ! n=30! Incidence: 89,000*!
2013 Accomplishments ! EPZ-6438 in 2015: Focus On Execution ! •
Generate data on Phase 1 dose escalation and expansion cohorts! – Present update on Phase 1 dose escalation cohort in mid-2015; of patients previously reported on, four NHL patients and one INI1-deficient patient remain on study! – Recently completed enrollment of 12 additional patients in Phase 1 dose expansion cohorts; data expected by year-end 2015!
•
Initiate five-arm Phase 2 study in non-Hodgkin lymphoma! – Study will prospectively stratify mutant and wild-type EZH2 patients, germinal and non-germinal center !
•
Initiate Phase 2 study in adult patients with INI1-deficient tumors and Phase 1 study in pediatric patients with INI1-deficient tumors! – Potential fast path to registration!
• • • !
20
!
Complete enrollment in food effect study and initiate drug-drug interaction study; present data from both studies 2H15! Continue to work collaboratively with FDA toward IND filing and subsequent Phase 2 initiation in US! Continue molecular characterization of patient samples from Phase 1 study!
26 MARCH 2015!
2013Worldwide Accomplishments Epizyme Regains Rights! to EPZ-6438! In March 2015, Epizyme regained worldwide rights to Epizyme-invented, first-in-class EZH2 inhibitor outside of Japan! • Key transaction in building independent, fully integrated oncology company! • Global control of clinical development, manufacturing and commercialization! • Favorable downstream economics:! – Exclusive worldwide commercial rights outside of Japan! – $40 million upfront payment to Eisai, up to $20 million in potential clinical milestone payments and up to $50 million in potential regulatory milestone payments! – Epizyme pays royalties in mid-teens on sales outside of Japan; Eisai pays royalties in midteens on sales in Japan!
!
21
• Eisai retains commercial rights in Japan and pays 100% of Japan-specific development costs; has limited right of first negotiation for Asia rights! 26 MARCH 2015!
Epizyme-owned EZH2 inhibitor with durable responses seen in multiple patient populations!
EPZ-5676
2013 Accomplishments! First-in-Class Small Molecule Inhibitor of DOT1L! •
Therapeutic mechanism of DOT1L inhibition and target methyl mark reduction results in anti-leukemic effects in cancers with MLL genetic alterations; no effects in cancers without MLL alterations!
•
Target indications: Orphan drug designation granted in US and EU! – MLL-r primary indication – genetically defined subset of AML and ALL, adult and pediatric!
•
Unmet need:! – MLL-r: Five-year overall survival rate in adult MLL-r acute leukemia ranges from 5 to 24 percent, no approved therapies specifically indicated for MLL-r !
•
Two CRs and one PR achieved in Phase 1 adult study! – Dose escalation stage – enrollment completed in 2013, allowed but did not require MLL-r patients!
– 90 mg/m2/day MLL-r expansion stage – completed in 2014!
•
Phase 1 MLL-r pediatric patient trial initiated in May 2014! – Enrolling patients between the ages of 3 months and 18 years to evaluate safety, PK, PD, with preliminary assessment of efficacy!
– PK modeling from study presented at ASH Annual Meeting 2014! ! !
22!
26 MARCH 2015!
EPZ-5676
2013 Accomplishments! Phase 1 Dose Escalation and Expansion Study! • • • • •
Primary Objectives: Define MTD or RP2D! Secondary Objectives: PK/PD, safety, activity! Advanced hematologic malignancies in dose escalation; MLL-r only in expansion! Extensively pre-treated: median number of prior systemic therapies: 2 (Range: 1 to 6)! Data cut-off: October 6, 2014! 90 mg/m2! 28-day CIV! !
Dose-proportional PK! 42 pts evaluable for safety and activity!
Exposure!
• •
80 mg/m2! 21-day CIV! ! 54 mg/m2! 21-day CIV! ! 36 mg/m2! 21-day CIV! !
24 mg/m2! 21-day CIV! ! 12 mg/m2! 21-day CIV! !
23!
Dose! 26 MARCH 2015!
Clinical and Biological Activity Observed in 9 2013 Accomplishments ! Patients! • 9 patients (8/34 MLL-r) had: ! – Marrow response and/or ! – Resolution of leukemia cutis and/or ! – Leukocytosis or differentiation! Dose! mg/m2/day!
Number of patients! (n=42)!
Marrow Response! (n=3)!
Leukemia cutis resolved ! (n=2)!
Leukocytosis or Differentiation! (n=8)!
12!
1!
-!
-!
-!
24!
5!
-!
-!
1!
36!
4!
-!
1!
2!
54!
6!
2 CR!
1!
1!
80!
3!
-!
-!
2!
90!
23!
1 PR!
-!
2!
(28 day CIV)! 24!
26 MARCH 2015!
2013 Accomplishments ! Acceptable Safety Profile! • Treatment-related adverse events (all grades): 16 patients (38%) ! – 10 patients < grade 2! • Majority gastrointestinal!
– 1 patient with grade 3 ! • Anemia (n=1)!
• Dose-limiting toxicities! – 90 mg/m2/d dose escalation cohort (n=6)! • None!
– 90 mg/m2/d expansion cohort (n=17)! • Grade 4 reversible cardiac failure with concurrent sepsis! • Grade 4 reversible hypophosphatemia during rapid WBC drop!
25!
26 MARCH 2015!
2013 Accomplishments EPZ-5676 2015 Planned Activities! ! • Enrolling < 20 MLL-r adult patients at 54 mg/m2/day! – Complete accrual expected 2H15!
• Complete molecular characterization of patient samples from expansion cohort to identify patient selection and response biomarkers! • Complete enrollment in Phase 1 pediatric study expected 2H15!
26!
26 MARCH 2015!
Pipeline: PRMT5 Shows In! Vitro and In 2013Inhibitor Accomplishments Vivo Activity in MCL Models! • EPZ015666 is a first-in-class potent, selective and orally bioavailable inhibitor of PRMT5; tool compound! – Demonstrated potent cellular activity as measured by its ability to block symmetric dimethylation and inhibit proliferation of MCL cell lines! – Displayed robust anti-tumor activity as a single agent in MCL xenograft animal models! • Pre-clinical studies of the effects of PRMT5 inhibition in other cancer indications are ongoing! • Partnered with GSK!
27!
26 MARCH 2015!
2013 Accomplishments ! Pipeline: First-in-Class PRMT5 Inhibitor for MCL !
Potent and Selective for PRMT5!
Novel NCE! Unique Binding Mode!
PD marker based on substrate methylation! 28!
Penebre et al. submitted!
Robust tumor growth inhibition! 26 MARCH 2015!
With correlated PD!
2013 Accomplishments ! Significant Strategic Partnering!
• $121 million to date, including equity! • Global partnership on EPZ-5676! Epizyme retains all US rights and funds Phase 1 studies! Celgene retains ex-US rights and pays royalties to mid-teens! $35 million remaining in potential clinical milestone payments! $100 million remaining in potential regulatory milestone payments!
• Option on all pipeline programs other than EZH2 is up for one-year renewal July 2015! • $165 million in potential milestones for each selected option program (ex-US)! $65 million in option and potential clinical milestone payments! $100 million in potential regulatory milestone payments! Royalty to mid-teens! 29!
• $53 million to date! • Epizyme delivered compounds against three targets, including first-in-class PRMT5 inhibitor! • GSK has global development and commercialization rights! • $620 million in remaining potential milestone payments for all three targets!
• Epizyme has global development and commercialization rights exJapan! • Epizyme made $40 million upfront payment to Eisai! • Epizyme pays up to $20 million in clinical milestones and up to $50 million in regulatory milestones! • Epizyme pays a mid-teens royalty for sales ex-Japan! • Eisai pays a mid-teens royalty for sales in Japan!
$18 million in potential preclinical milestone payments! $109 million in potential clinical milestone payments! $275 in potential regulatory milestone payments! $218 in potential sales-based milestone payments!
• WW royalties up to low double digits! 26 MARCH 2015!
!
2013 Accomplishments! Financial Overview! • Ended 2014 with $190.1 million in cash and cash equivalents! – In addition, raised gross proceeds of $124.5 million in a follow-on offering in March 2015! – Expected runway through at least year-end 2016!
• Shares outstanding as of December 31, 2014: 34.4 million! – Issued additional 6.0 million shares in secondary public offering!
• Fully diluted shares outstanding as of December 31, 2014: 37.4 million! 30!
!
26 MARCH 2015!
2013throughout Accomplishments Multiple Catalysts 2015!! ü Completed accrual of 12 patients in EPZ-6438 Phase 1 dose expansion cohorts! – Present updated dose escalation data mid-2015! – Present dose expansion data before the end of 2015!
• Initiate EPZ-6438 Phase 2 studies! – Five-arm NHL study with prospective stratification of EZH2 mutant and wild-type patients, germinal and non-germinal center, initiation expected in 2Q15! •
Germinal center DLBCL with wild-type EZH2 and non-germinal center DLBCL arms expected to read out mid-2016!
– INI1-deficient adult study and Phase 1 pediatric study!
•
Complete enrollment in food effect study and initiate drug-drug interaction study; present data from both studies 2H15!
• Complete accrual of up to 20 patients in EPZ-5676 54 mg/m2/day expansion cohort in 2H15! – Present data in late 2015/early 2016!
• Complete enrollment in EPZ-5676 Phase 1 pediatric study expected in 2H15! – Present data in 2016!
• Present discovery research on HMT targets at AACR annual meeting: CARM1, SETDB1, SMYD3, PRMT6! • Patent publications and issuances expected in 2015!
! 31!
26 MARCH 2015!
2013 Accomplishments!
www.epizyme.com!
26 MARCH 2015!
